Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

The Availability Heuristic

The Availability Heuristic

A heuristic is a general problem-solving framework (Tversky & Kahneman, 1974). You can think of these as mental shortcuts that are used to solve problems. Different types of heuristics are used in different types of situations, and the impulse to use a heuristic occurs when one of five conditions is met (Pratkanis, 1989):

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Resistance to anti-PD-1 immunotherapy for stage III and IV melanoma: a global chart review study.

Journal for immunotherapy of cancer·2026

Same author

Brain age prediction in a multiethnic Asian population: A comparison of machine learning algorithms and their application for early-stage cognitive impairment diagnosis.

Journal of Alzheimer's disease : JAD·2026

Same author

Exploratory Analysis of Biomarkers and Treatment Outcomes from the COLUMBUS Study in BRAF V600E/K-Mutant Advanced or Metastatic Melanoma.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Same author

Homologous Recombination Deficiency in Skin Cancers: Prevalence and Clinical Implications of This Distinct Patient Cohort.

JCO precision oncology·2026

Same author

Surgical treatment of vaginal and vulvar melanoma: a 18-year retrospective study.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·2026

Same author

International real-world study of combination immunotherapy sequences in metastatic melanoma.

Journal for immunotherapy of cancer·2025

Search research articles

Related Experiment Video

Updated: Mar 16, 2026

High-throughput Fluorometric Measurement of Potential Soil Extracellular Enzyme Activities

High-throughput Fluorometric Measurement of Potential Soil Extracellular Enzyme Activities

Published on: November 15, 2013

[Not Available].

Christine Mateus¹, Cristina Libenciuc¹, Caroline Robert¹

¹Service de dermatologie, Gustave Roussy, Université Paris-Saclay, Département de Médecine Oncologique, Villejuif, F-94805, France.

Bulletin Du Cancer

|August 7, 2016

Summary

Immune checkpoint inhibitors targeting PD-1 offer improved survival and lower toxicity for metastatic melanoma patients compared to older therapies. Combination therapies show higher response rates but increased adverse events.

Keywords:

Anti-PD1 Immunotherapy Immunothérapie Mestastatic melanoma Mélanome métastatique Nivolumab Pembrolizumab

More Related Videos

Ex Vivo Assessment of Contractility, Fatigability and Alternans in Isolated Skeletal Muscles

Ex Vivo Assessment of Contractility, Fatigability and Alternans in Isolated Skeletal Muscles

Published on: November 1, 2012

A Submerged Filter Paper Sandwich for Long-term Ex Ovo Time-lapse Imaging of Early Chick Embryos

A Submerged Filter Paper Sandwich for Long-term Ex Ovo Time-lapse Imaging of Early Chick Embryos

Published on: December 28, 2016

Related Experiment Videos

Last Updated: Mar 16, 2026

High-throughput Fluorometric Measurement of Potential Soil Extracellular Enzyme Activities

High-throughput Fluorometric Measurement of Potential Soil Extracellular Enzyme Activities

Published on: November 15, 2013

Ex Vivo Assessment of Contractility, Fatigability and Alternans in Isolated Skeletal Muscles

Ex Vivo Assessment of Contractility, Fatigability and Alternans in Isolated Skeletal Muscles

Published on: November 1, 2012

A Submerged Filter Paper Sandwich for Long-term Ex Ovo Time-lapse Imaging of Early Chick Embryos

A Submerged Filter Paper Sandwich for Long-term Ex Ovo Time-lapse Imaging of Early Chick Embryos

Published on: December 28, 2016

Area of Science:

Oncology
Immunology
Dermatology

Background:

Metastatic melanoma treatment has advanced significantly with targeted therapies and immunotherapies.
Previous attempts with cytokines and vaccines showed limited prognostic improvement.
Immune checkpoint inhibitors, including anti-CTLA-4 and anti-PD1, represent a major therapeutic breakthrough.

Purpose of the Study:

To review the role and advancements of anti-PD1 therapy in cutaneous melanoma treatment.
To compare the efficacy and toxicity of anti-PD1 antibodies with previous treatments.
To identify unresolved questions and future directions in melanoma immunotherapy.

Main Methods:

Review of clinical data and therapeutic outcomes for metastatic melanoma.
Comparison of response rates, overall survival, and toxicity profiles of different treatments.
Analysis of emerging combination therapies and treatment settings.

Main Results:

Anti-PD1 antibodies (pembrolizumab, nivolumab) demonstrate response rates of 30-40% with improved survival and less toxicity than ipilimumab.
Targeted anti-BRAF and anti-MEK therapies are options for BRAFV600 mutated melanoma.
Combination of ipilimumab and nivolumab shows higher response rates (50-57%) but increased severe adverse events (>50%).

Conclusions:

Anti-PD1 antibodies are a new standard of care for metastatic melanoma, offering significant survival benefits.
Key questions remain regarding first-line indications, combination strategies, treatment duration, and adjuvant settings.
Combination immunotherapy presents a promising but more toxic alternative for advanced melanoma.